Abstract: The present disclosure is related to devices, systems, and methods for extensibility for custom day-2 operations on cloud resources. One example includes receiving an indication of a resource type of a software-defined datacenter via an interface of a cloud automation platform, receiving an indication of an ABX action via the interface, associating the resource type with the ABX action to create a resource action responsive to an input via the interface, and deploying a blueprint containing a resource of the resource type, wherein the resource action is executable to modify an internal state of the resource.

Abstract: Custom resource schema modification is described herein. One example method includes providing an interface for modifying a schema of a custom resource in a virtualized environment. The interface can include a first portion configured to receive modifications to summary information corresponding to the custom resource and a second portion configured to receive modifications to properties corresponding to the schema of the custom resource. The method can include validating the modified schema, and saving the modified schema of the custom resource responsive to the validation being successful.

Abstract: The present disclosure relates to extending workload provisioning using a low-code development platform. Some embodiments include a medium having instructions to provide an interface for creating a custom resource in a virtualized environment, the interface including a first portion configured to receive summary information corresponding to the custom resource, and a second portion configured to receive a schema corresponding to the custom resource. Some embodiments include creating the custom resource according to the summary information and the schema.

Abstract: The present invention relates to an N-terminal fragment of an angiopoietin like 4 (ANGPTL4) polypeptide, or a therapeutically active variant thereof, for use in the treatment of cancer in a subject. Moreover, the present invention provides an agent which increases the amount of an N-terminal fragment of an angiopoietin like 4 (ANGPTL4) polypeptide for use in treating cancer. Further, encompassed by the present invention is a method for identifying a candidate compound for the treatment of cancer.